Otology & Neurotology · 2012 · 253 citations · 25 references
MedicineOncologyOtolaryngologyNeuro-oncologyNeurotologyOtologyHearing ImpairmentHearing LossOtologic SurgeryVestibular SchwannomaNeurofibromatosis Type 2-Associated TumorsNeurofibromatosis-associated TumorsProgressive Hearing LossTumor Growth DynamicsTumor Growth RateTumor Shrinkage AssessmentTumor Volume MeasurementVestibular Nerve Tumors
Early studies suggest that bevacizumab can shrink vestibular schwannomas and improve hearing in patients with neurofibromatosis type 2. The study reports extended follow‑up of bevacizumab treatment in a larger cohort of NF2 patients with progressive vestibular schwannomas. In a retrospective cohort of 31 NF2 patients (median age 26 yr), bevacizumab was given for a median of 14 months (range 6–41 mo), with a pre‑treatment tumor growth rate of 64 % per year and 47 patient‑years of follow‑up. Bevacizumab produced hearing improvement in 57 % and radiographic tumor shrinkage in 55 % of patients, with median response at 3 months; 90 % maintained hearing and 88 % had stable or reduced tumor size at 1 year, and the treatment was well tolerated.
Early studies suggest that bevacizumab treatment can result in tumor shrinkage and hearing improvement for some patients with neurofibromatosis type 2 (NF2). The aim of this study was to report extended follow-up in a larger cohort of similarly treated patients.Retrospective study.Tertiary referral centerThirty-one consecutive NF2 patients who received bevacizumab for progressive vestibular schwannomas.Hearing improvement, defined as an improvement in word recognition score above the 95% critical difference compared with baseline, and radiographic response, defined as a 20% or greater decrease in tumor volume compared with baseline.The median age was 26 years (range, 12-73 yr). The median volumetric tumor growth rate before treatment was 64% per year. At the time of analysis, the median duration of treatment was 14 months (range, 6-41 mo) with a total of 47 patient-years of follow-up. A hearing response occurred in 57% (13/23) of evaluable patients and a radiographic response in 55% (17/31) of target vestibular schwannomas. The median time to response was 3 months for both end points. The only clinical or radiographic feature at baseline that correlated with change in tumor volume at 3 months was the mean apparent diffusion coefficient value, a radiologic marker of edema (p = 0.036). Ninety percent of patients had stable or improved hearing after 1 year of treatment and 61% at 3 years; 88% of patients had stable or decreased tumor size after 1 year of treatment and 54% at 3 years. Overall, treatment was well tolerated.Bevacizumab treatment was followed by hearing improvement and tumor shrinkage in more than 50% of progressive vestibular schwannomas in NF2 patients. Stable or improved hearing was retained in the majority of patients.
25
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman, Michael D. Prados, Patrick Y. Wen et al. · Journal of Clinical Oncology · 2009 · 2.4K citations
Medicine, Oncology, Pharmacology +17
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
John M.L. Ebos, Christina R. Lee, William Cruz‐Muñoz et al. · Cancer Cell · 2009 · 1.7K citations · Full text
Medicine, Oncology, Pharmacology +16
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
Michael R. Mancuso, Rachel Davis, Scott M. Norberg et al. · Journal of Clinical Investigation · 2006 · 798 citations · Full text
Medicine, Oncology, Pharmacology +14